Do analysts rate JMAC or ATHE?

Alterity Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 171.63%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Maxpro Capital Acquisition. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Maxpro Capital Acquisition 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Alterity Therapeutics 1 Sell rating(s) 1 Hold rating(s) 3 Buy rating(s) 0 Strong Buy rating(s) 2.40

Which has higher valuation & earnings, JMAC or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Maxpro Capital Acquisition N/A N/A N/A N/A N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is JMAC or ATHE more profitable?

Company Net Margins Return on Equity Return on Assets Maxpro Capital Acquisition N/A N/A N/A Alterity Therapeutics N/A N/A N/A

Which has preferable valuation & earnings, ARCT or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Arcturus Therapeutics $82.03M 2.04 -$65.78M -$2.81 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Does the media prefer ARCT or ATHE?

In the previous week, Arcturus Therapeutics had 4 more articles in the media than Alterity Therapeutics. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 2 mentions for Alterity Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.16 beat Alterity Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Arcturus Therapeutics 4 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has stronger earnings and valuation, ABOS or ATHE?

Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Acumen Pharmaceuticals N/A N/A -$121.33M -$1.86 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is ABOS or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity. Company Net Margins Return on Equity Return on Assets Acumen Pharmaceuticals N/A -123.07% -79.41% Alterity Therapeutics N/A N/A N/A

Does the media refer more to ABOS or ATHE?

In the previous week, Alterity Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat Alterity Therapeutics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Acumen Pharmaceuticals 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Alterity Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, WHWK or ATHE?

Alterity Therapeutics has lower revenue, but higher earnings than Whitehawk Therapeutics. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Whitehawk Therapeutics $7.14M 27.29 -$20.60M -$1.68 N/A Alterity Therapeutics N/A N/A -$7.87M N/A N/A

Is WHWK or ATHE more profitable?

Alterity Therapeutics' return on equity of 0.00% beat Whitehawk Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Whitehawk Therapeutics N/A -79.63% -74.01% Alterity Therapeutics N/A N/A N/A

Which has preferable earnings and valuation, ATHE or DERM?

Alterity Therapeutics has higher earnings, but lower revenue than Journey Medical. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Alterity Therapeutics N/A N/A -$7.87M N/A N/A Journey Medical $61.86M 3.27 -$11.43M -$0.37 N/A

Alterity Therapeutics (ATHE) Competitors

$4.88 -0.11 (-2.11%)

As of 11:43 AM Eastern

Compare

ATHE vs. JMAC, ARCT, ABOS, WHWK, and DERM

Should you buy Alterity Therapeutics stock or one of its competitors? MarketBeat compares Alterity Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Alterity Therapeutics include Maxpro Capital Acquisition (JMAC), Arcturus Therapeutics (ARCT), Acumen Pharmaceuticals (ABOS), Whitehawk Therapeutics (WHWK), and Journey Medical (DERM). These companies are all part of the "pharmaceutical products" industry.

How does Alterity Therapeutics compare to Maxpro Capital Acquisition?

Maxpro Capital Acquisition (NASDAQ:JMAC) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap pharmaceutical products companies, but which is the better stock? We will compare the two companies based on the strength of their analyst recommendations, profitability, media sentiment, institutional ownership, risk, valuation, earnings and dividends.

73.2% of Maxpro Capital Acquisition shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 19.3% of Maxpro Capital Acquisition shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

In the previous week, Alterity Therapeutics had 2 more articles in the media than Maxpro Capital Acquisition. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Maxpro Capital Acquisition. Maxpro Capital Acquisition's average media sentiment score of 0.00 equaled Alterity Therapeutics'average media sentiment score.

Company	Overall Sentiment
Maxpro Capital Acquisition	Neutral
Alterity Therapeutics	Neutral

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Alterity Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 171.63%. Given Alterity Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Maxpro Capital Acquisition.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Maxpro Capital Acquisition	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	0.00
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Maxpro Capital Acquisition has a beta of 0.01, meaning that its share price is 99% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, meaning that its share price is 75% less volatile than the broader market.

Company	Net Margins	Return on Equity	Return on Assets
Maxpro Capital Acquisition	N/A	N/A	N/A
Alterity Therapeutics	N/A	N/A	N/A

Summary

Alterity Therapeutics beats Maxpro Capital Acquisition on 6 of the 7 factors compared between the two stocks.

How does Alterity Therapeutics compare to Arcturus Therapeutics?

Arcturus Therapeutics (NASDAQ:ARCT) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their media sentiment, risk, institutional ownership, earnings, profitability, dividends, valuation and analyst recommendations.

Alterity Therapeutics has a net margin of 0.00% compared to Arcturus Therapeutics' net margin of -143.80%. Alterity Therapeutics' return on equity of 0.00% beat Arcturus Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Arcturus Therapeutics	-143.80%	-36.55%	-28.40%
Alterity Therapeutics	N/A	N/A	N/A

94.5% of Arcturus Therapeutics shares are owned by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are owned by institutional investors. 17.8% of Arcturus Therapeutics shares are owned by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.

Arcturus Therapeutics has a beta of 2.37, indicating that its share price is 137% more volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, indicating that its share price is 75% less volatile than the broader market.

Alterity Therapeutics has lower revenue, but higher earnings than Arcturus Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Arcturus Therapeutics	$82.03M	2.04	-$65.78M	-$2.81	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

In the previous week, Arcturus Therapeutics had 4 more articles in the media than Alterity Therapeutics. MarketBeat recorded 6 mentions for Arcturus Therapeutics and 2 mentions for Alterity Therapeutics. Arcturus Therapeutics' average media sentiment score of 1.16 beat Alterity Therapeutics' score of 0.00 indicating that Arcturus Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Arcturus Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Arcturus Therapeutics presently has a consensus target price of $24.25, suggesting a potential upside of 312.06%. Alterity Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 171.63%. Given Arcturus Therapeutics' stronger consensus rating and higher possible upside, equities analysts plainly believe Arcturus Therapeutics is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Arcturus Therapeutics	1 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.64
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Summary

Arcturus Therapeutics beats Alterity Therapeutics on 9 of the 14 factors compared between the two stocks.

How does Alterity Therapeutics compare to Acumen Pharmaceuticals?

Acumen Pharmaceuticals (NASDAQ:ABOS) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their valuation, institutional ownership, analyst recommendations, profitability, dividends, risk, media sentiment and earnings.

Acumen Pharmaceuticals has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

In the previous week, Alterity Therapeutics had 1 more articles in the media than Acumen Pharmaceuticals. MarketBeat recorded 2 mentions for Alterity Therapeutics and 1 mentions for Acumen Pharmaceuticals. Acumen Pharmaceuticals' average media sentiment score of 0.33 beat Alterity Therapeutics' score of 0.00 indicating that Acumen Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Acumen Pharmaceuticals	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Alterity Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

71.0% of Acumen Pharmaceuticals shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 10.2% of Acumen Pharmaceuticals shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Acumen Pharmaceuticals presently has a consensus target price of $8.00, suggesting a potential upside of 266.13%. Alterity Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 171.63%. Given Acumen Pharmaceuticals' higher possible upside, equities analysts plainly believe Acumen Pharmaceuticals is more favorable than Alterity Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Acumen Pharmaceuticals	1 Sell rating(s)	0 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.33
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alterity Therapeutics' return on equity of 0.00% beat Acumen Pharmaceuticals' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Acumen Pharmaceuticals	N/A	-123.07%	-79.41%
Alterity Therapeutics	N/A	N/A	N/A

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Acumen Pharmaceuticals	N/A	N/A	-$121.33M	-$1.86	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

Summary

Alterity Therapeutics beats Acumen Pharmaceuticals on 7 of the 11 factors compared between the two stocks.

How does Alterity Therapeutics compare to Whitehawk Therapeutics?

Whitehawk Therapeutics (NASDAQ:WHWK) and Alterity Therapeutics (NASDAQ:ATHE) are both small-cap pharmaceutical products companies, but which is the better investment? We will compare the two businesses based on the strength of their earnings, institutional ownership, profitability, analyst recommendations, risk, valuation, dividends and media sentiment.

Alterity Therapeutics has lower revenue, but higher earnings than Whitehawk Therapeutics.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Whitehawk Therapeutics	$7.14M	27.29	-$20.60M	-$1.68	N/A
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A

In the previous week, Alterity Therapeutics had 2 more articles in the media than Whitehawk Therapeutics. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Whitehawk Therapeutics. Whitehawk Therapeutics' average media sentiment score of 1.94 beat Alterity Therapeutics' score of 0.00 indicating that Whitehawk Therapeutics is being referred to more favorably in the media.

Company	Overall Sentiment
Whitehawk Therapeutics	Very Positive
Alterity Therapeutics	Neutral

52.1% of Whitehawk Therapeutics shares are held by institutional investors. Comparatively, 2.1% of Alterity Therapeutics shares are held by institutional investors. 49.9% of Whitehawk Therapeutics shares are held by insiders. Comparatively, 38.8% of Alterity Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Whitehawk Therapeutics has a beta of 0.77, suggesting that its stock price is 23% less volatile than the broader market. Comparatively, Alterity Therapeutics has a beta of 0.25, suggesting that its stock price is 75% less volatile than the broader market.

Whitehawk Therapeutics presently has a consensus target price of $8.20, suggesting a potential upside of 108.12%. Alterity Therapeutics has a consensus target price of $13.00, suggesting a potential upside of 171.63%. Given Alterity Therapeutics' higher probable upside, analysts clearly believe Alterity Therapeutics is more favorable than Whitehawk Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Whitehawk Therapeutics	1 Sell rating(s)	1 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.63
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Alterity Therapeutics' return on equity of 0.00% beat Whitehawk Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Whitehawk Therapeutics	N/A	-79.63%	-74.01%
Alterity Therapeutics	N/A	N/A	N/A

Summary

Whitehawk Therapeutics beats Alterity Therapeutics on 7 of the 12 factors compared between the two stocks.

How does Alterity Therapeutics compare to Journey Medical?

Alterity Therapeutics (NASDAQ:ATHE) and Journey Medical (NASDAQ:DERM) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Alterity Therapeutics has a beta of 0.25, indicating that its stock price is 75% less volatile than the broader market. Comparatively, Journey Medical has a beta of 1.07, indicating that its stock price is 7% more volatile than the broader market.

Alterity Therapeutics has higher earnings, but lower revenue than Journey Medical.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Alterity Therapeutics	N/A	N/A	-$7.87M	N/A	N/A
Journey Medical	$61.86M	3.27	-$11.43M	-$0.37	N/A

Alterity Therapeutics has a net margin of 0.00% compared to Journey Medical's net margin of -14.82%. Alterity Therapeutics' return on equity of 0.00% beat Journey Medical's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Alterity Therapeutics	N/A	N/A	N/A
Journey Medical	-14.82%	-35.57%	-10.88%

2.1% of Alterity Therapeutics shares are owned by institutional investors. Comparatively, 7.3% of Journey Medical shares are owned by institutional investors. 38.8% of Alterity Therapeutics shares are owned by insiders. Comparatively, 14.5% of Journey Medical shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Alterity Therapeutics currently has a consensus target price of $13.00, suggesting a potential upside of 171.63%. Journey Medical has a consensus target price of $13.00, suggesting a potential upside of 77.09%. Given Alterity Therapeutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe Alterity Therapeutics is more favorable than Journey Medical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Alterity Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Journey Medical	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Alterity Therapeutics had 2 more articles in the media than Journey Medical. MarketBeat recorded 2 mentions for Alterity Therapeutics and 0 mentions for Journey Medical. Alterity Therapeutics' average media sentiment score of 0.00 equaled Journey Medical'saverage media sentiment score.

Company	Overall Sentiment
Alterity Therapeutics	Neutral
Journey Medical	Neutral

Summary

Alterity Therapeutics beats Journey Medical on 9 of the 12 factors compared between the two stocks.

Get Alterity Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding ATHE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

ATHE vs. The Competition

Export

Metric	Alterity Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$42.51M	$3.66B	$6.81B	$12.38B
Dividend Yield	N/A	2.18%	2.67%	9.67%
P/E Ratio	N/A	20.57	26.91	24.08
Price / Sales	N/A	165.58	492.94	77.67
Price / Cash	N/A	150.24	49.71	59.37
Price / Book	1.54	8.10	10.49	6.20
Net Income	-$7.87M	$23.81M	$3.60B	$331.56M
7 Day Performance	-4.09%	-2.59%	-1.59%	-1.37%
1 Month Performance	-2.92%	0.04%	0.75%	-1.86%
1 Year Performance	-7.25%	42.33%	23.25%	17.85%

Alterity Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
ATHE Alterity Therapeutics	2.9226 of 5 stars	$4.88 -2.1%	$13.00 +166.7%	-1.0%	$43.23M	N/A	N/A	10	News Coverage Gap Down
JMAC Maxpro Capital Acquisition	N/A	$14.21 -25.0%	N/A	+203.7%	$190.81M	N/A	N/A	2,021	Gap Up
ARCT Arcturus Therapeutics	2.6905 of 5 stars	$6.37 -5.1%	$24.25 +280.7%	-56.6%	$190.72M	$82.03M	N/A	180	Positive News
ABOS Acumen Pharmaceuticals	2.2628 of 5 stars	$2.53 -4.2%	$8.00 +216.2%	+43.9%	$190.68M	N/A	N/A	20
WHWK Whitehawk Therapeutics	2.859 of 5 stars	$3.81 -0.8%	$8.20 +115.2%	+111.4%	$189.90M	$7.14M	N/A	21

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:ATHE) was last updated on 7/22/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Alterity Therapeutics (ATHE) Competitors

ATHE vs. JMAC, ARCT, ABOS, WHWK, and DERM

How does Alterity Therapeutics compare to Maxpro Capital Acquisition?

Summary

How does Alterity Therapeutics compare to Arcturus Therapeutics?

Summary

How does Alterity Therapeutics compare to Acumen Pharmaceuticals?

Summary

How does Alterity Therapeutics compare to Whitehawk Therapeutics?

Summary

How does Alterity Therapeutics compare to Journey Medical?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Alterity Therapeutics (ATHE) Competitors

ATHE vs. JMAC, ARCT, ABOS, WHWK, and DERM

How does Alterity Therapeutics compare to Maxpro Capital Acquisition?

Do institutionals & insiders have more ownership in JMAC or ATHE?

Does the media prefer JMAC or ATHE?

Which has higher valuation & earnings, JMAC or ATHE?

Do analysts rate JMAC or ATHE?

Which has more volatility & risk, JMAC or ATHE?

Is JMAC or ATHE more profitable?

Summary

How does Alterity Therapeutics compare to Arcturus Therapeutics?

Is ARCT or ATHE more profitable?

Do institutionals & insiders have more ownership in ARCT or ATHE?

Which has more risk and volatility, ARCT or ATHE?

Which has preferable valuation & earnings, ARCT or ATHE?

Does the media prefer ARCT or ATHE?

Do analysts prefer ARCT or ATHE?

Summary

How does Alterity Therapeutics compare to Acumen Pharmaceuticals?

Which has more risk and volatility, ABOS or ATHE?

Does the media refer more to ABOS or ATHE?

Do institutionals and insiders hold more shares of ABOS or ATHE?

Do analysts rate ABOS or ATHE?

Is ABOS or ATHE more profitable?

Which has stronger earnings and valuation, ABOS or ATHE?

Summary

How does Alterity Therapeutics compare to Whitehawk Therapeutics?

Which has higher earnings & valuation, WHWK or ATHE?

Does the media prefer WHWK or ATHE?

Do insiders & institutionals hold more shares of WHWK or ATHE?

Which has more volatility & risk, WHWK or ATHE?

Do analysts recommend WHWK or ATHE?

Is WHWK or ATHE more profitable?

Summary

How does Alterity Therapeutics compare to Journey Medical?

Which has more risk & volatility, ATHE or DERM?

Which has preferable earnings and valuation, ATHE or DERM?

Is ATHE or DERM more profitable?

Do insiders & institutionals have more ownership in ATHE or DERM?

Do analysts recommend ATHE or DERM?

Does the media refer more to ATHE or DERM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

ATHE vs. The Competition

Alterity Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools